Immuno-Oncology | Specialty

HPV Infection in Pathogenesis of Head and Neck Cancers

March 21st 2016

Biology of Head and Neck Squamous Cell Carcinoma

March 21st 2016

Trial Tests Combo of Pexidartinib and Pembrolizumab in Ovarian and Other Solid Tumors

March 21st 2016

An ongoing clinical trial has begun the process of evaluating whether the addition of a booster agent can take the anticancer activity of PD-1 directed immunotherapy to another level.

Mittendorf Explains Growing Role of Checkpoint Inhibitors in Breast Cancer

March 21st 2016

Elizabeth Mittendorf, MD, PhD, discusses checkpoint inhibition studies in triple-negative breast cancer, potential ways to make other subtypes more immunogenic to improve response, the role of PD-1, and what’s next in the field of immunotherapy in breast cancer.

CAR T-cells Rapidly Evolving as Cancer Therapies

March 20th 2016

Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.

Potential of Immuno-Oncology Continues to Expand

March 19th 2016

Immuno-oncology has advanced rapidly, with the introduction of immune checkpoint inhibition and effective adoptive T-cell therapies. As these agents rush through development, several questions remain regarding the optimal patients for treatment and the next steps for further improving outcomes.

Dr. Krajewski on Responses With PD-1 Agents in RCC

March 17th 2016

Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.

Expert on PD-L1/CTLA-4 Blockade and Future of Immunotherapy in Lung Cancer

March 17th 2016

Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non–small cell lung cancer, irrespective of PD-L1 status.

Dr. Chandra Belani on Atezolizumab in NSCLC

March 16th 2016

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

The New Front Line in Melanoma: Immunotherapy or Targeted Agents?

March 16th 2016

The bounty of choices is good news for patients with melanoma, several key questions have emerged: Should immunotherapy or targeted agents be the first-line choice for metastatic melanoma?

FDA Grants Atezolizumab Priority Review in Bladder Cancer

March 15th 2016

The FDA has granted a priority review to atezolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.

Atezolizumab Approaches FDA Approval in Bladder Cancer, But Biomarkers Remain Unclear

March 15th 2016

Matthew Galsky, MD, explains the challenges of utilizing molecular subtyping and PD-L1 as biomarkers, the impact a potential approval of atezolizumab could have in metastatic bladder cancer, possible combinations that could increase ORR, and next steps in understanding the IMvigor study.

Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

March 14th 2016

James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Nivolumab Practice-Changing in RCC, But Biomarkers Still Critical for Progress

March 9th 2016

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

Nivolumab, Pembrolizumab Compete for Top Choice in NSCLC Treatment

March 8th 2016

Benjamin Levy, MD, discusses how nivolumab and pembrolizumab have impacted the treatment landscape of NSCLC, how to choose between the two for patients, and what biomarkers are in development for PD-1/PD-L1 agents.

FDA Accepts Application to Expand Pembrolizumab NSCLC Indication

March 7th 2016

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma

March 7th 2016

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

Will Immunotherapy or Targeted Therapy Take the Lead in Melanoma?

March 5th 2016

Michael Atkins, MD, discusses his views on the potential of immunotherapy versus targeted therapy in melanoma, what research has shown so far, and what could be on horizon for both classes of drugs going forward.

Dr. Belani on Impact of Nivolumab's Approval in NSCLC

March 4th 2016

Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).

Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

March 3rd 2016

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.